Citadel Advisors
KNSA icon

Citadel Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Citadel Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$631K Buy
+13,100
New +$580K ﹤0.01% 8730
2025
Q4 		– Sell
-14,100
Closed -$548K – 13441
2025
Q3 		$548K Sell
14,100
-18,100
-56% -$588K ﹤0.01% 8910
2025
Q2 		$891K Buy
32,200
+20,100
+166% +$512K ﹤0.01% 7364
2025
Q1 		$269K Buy
12,100
+6,800
+128% +$140K ﹤0.01% 9835
2024
Q4 		$105K Sell
5,300
-4,400
-45% -$100K ﹤0.01% 11422
2024
Q3 		$242K Buy
9,700
+1,800
+23% +$43.9K ﹤0.01% 9748
2024
Q2 		$147K Sell
7,900
-1,200
-13% -$22.5K ﹤0.01% 10376
2024
Q1 		$180K Sell
9,100
-2,800
-24% -$54.7K ﹤0.01% 10493
2023
Q4 		$209K Sell
11,900
-4,500
-27% -$74K ﹤0.01% 9873
2023
Q3 		$285K Buy
16,400
+1,500
+10% +$25.3K ﹤0.01% 9269
2023
Q2 		$210K Sell
14,900
-130,700
-90% -$1.75M ﹤0.01% 9779
2023
Q1 		$1.57M Sell
145,600
-16,200
-10% -$213K ﹤0.01% 5836
2022
Q4 		$2.42M Buy
161,800
+86,100
+114% +$1.25M ﹤0.01% 5124
2022
Q3 		$972K Buy
75,700
+3,400
+5% +$38.7K ﹤0.01% 7053
2022
Q2 		$701K Buy
72,300
+34,500
+91% +$322K ﹤0.01% 7868
2022
Q1 		$376K Buy
37,800
+27,300
+260% +$289K ﹤0.01% 10067
2021
Q4 		$124K Sell
10,500
-20,200
-66% -$248K ﹤0.01% 12487
2021
Q3 		$350K Buy
30,700
+6,500
+27% +$84.6K ﹤0.01% 10714
2021
Q2 		$337K Buy
24,200
+1,400
+6% +$21.3K ﹤0.01% 10987
2021
Q1 		$422K Sell
22,800
-4,600
-17% -$94.1K ﹤0.01% 10055
2020
Q4 		$484K Sell
27,400
-4,600
-14% -$80.8K ﹤0.01% 8200
2020
Q3 		$490K Buy
32,000
+20,800
+186% +$391K ﹤0.01% 7340
2020
Q2 		$285K Buy
+11,200
New +$234K ﹤0.01% 7988

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Citadel Advisors's KNSA Position: Q1 2026 in Review

Citadel Advisors reduced its Kiniksa Pharmaceuticals (KNSA) stake by 36% in Q1 2026, selling an estimated $11.8M and leaving 474,750 shares worth $22.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2167.

Citadel Advisors first reported a position in KNSA in Q2 2018 and has held it in 32 quarters since. The position peaked at $30.6M in Q4 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Citadel Advisors held 474,750 shares of Kiniksa Pharmaceuticals worth $22.9M as of Q1 2026.
  • Citadel Advisors sold 267,368 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $11.8M.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2167 holding.
  • Citadel Advisors first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
  • Citadel Advisors's Kiniksa Pharmaceuticals position peaked at $30.6M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.